NASDAQ:ARPO

As of August 26, 2021, Aerpio Pharmaceuticals, Inc. was acquired by Aadi Bioscience, Inc., in a reverse merger transaction. Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company’s lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.